IMS Institute estimates biosimilar savings

In a Humira adalimumab from AbbVie Inc. (NYSE:ABBV), Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY), Enbrel etanercept and Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN), Remicade ...